Background: Differential co-expression signifies change in degree of co-expression of a set of genes among different biological conditions. It has been used to identify differential co-expression networks or interactomes. Many algorithms have been developed for single-factor differential co-expression analysis and applied in a variety of studies. However, in many studies, the samples are characterized by multiple factors such as genetic markers, clinical variables and treatments. No algorithm or methodology is available for multi-factor analysis of differential co-expression.
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Background
Differential co-expression of a set of genes is the change in their degree of coexpression among two or more relevant biological conditions [12] . As illustrated in Figure 1 , differentially co-expressed genes demonstrate a strong co-expression pattern among normal samples and no co-expression among disease samples. These genes may not be differentially expressed. Differential co-expression signifies loss of control of factor(s) over the respective downstream genes in a set of samples compared to the samples in which the gene set is co-expressed or variable influence of a factor in one set of samples over the other. This could also be due to a latent factor which had a significant influence on gene expression in a particular condition [44] .
Since the proposal by Kostka & Spang [12] , many algorithms have been proposed to identify differentially co-expressed (referred as DCX throughout the paper) gene sets and quantify differential co-expression. The algorithms can be classified based on two criteria: (1) method of identification of DCX gene sets (targeted, semi-targeted and untargeted); and (2) scoring method of differential co-expression (gene set scoring and gene-pair scoring).
Based on the method of identification, similar to the one described by Tesson et al. [2] , the algorithms can be classified into targeted, semi-targeted and untargeted algorithms. The Targeted algorithms [9] perform differential co-expression analysis on predefined sets of genes. The candidate gene sets may be obtained from public databases such as GO categories and KEGG pathways. They do not find novel sets of DCX gene sets. Another disadvantage of targeted methods is their reduced sensitivity if only a subset of the given gene set is differentially co-expressed as the DCX signal is diluted and the DCX geneset may not be identified. In addition, the DCX gene sets that are composed of genes of multiple biological processes or functions [44] may not be identified at all. The semi-targeted algorithms [2, 17, 24] work on the observation that the genes are co-expressed in one group of samples. Hence they perform clustering of genes in one set of samples, identify gene sets tightly co-expressed and test for their differential co-expression using the remaining group of samples.
Although semi-targeted algorithms can identify novel gene sets, their applicability is limited to the co-expressed sets identified by the clustering algorithm. On the other hand, the untargeted algorithms [10, 12, 29] assume no prior candidate sets of genes and instead find the gene sets in an exploratory manner and therefore have a high potential to identify novel gene sets. The major drawback of untargeted approach is potentially high false discovery rate and large computational requirements.
The second aspect of DCX gene set identification algorithms is the methodology employed in scoring differential co-expression of a given gene set: (1) gene set scoring or set-wise method, and (2) gene pair scoring. In gene set scoring, all genes are considered in the scoring at once such as in the linear modelling used in Kostka & Spang [12] and Prieto et al. [10] . On the other hand, gene-pair scoring, as used in DiffFNs [29] and DCoX [2] , computes differential correlation of each pair of genes in the gene set and summarizes them to obtain DCX score for the gene set. Gene pair scoring is intuitive and amenable to network like visualization and interpretation in single factor analysis settings. However, gene set scoring can be thought of as gene network of multiple cliques and cliques connected via common genes among all pairs of gene sets. The first few methods (e.g. Kostka & Spang [12] and Prieto et al. [10] ) are untargeted set-wise methods, while DiffFNs [29] is an untargeted gene-pair scoring method. However, many later methods, including an early method (DCA [17] ) are predominantly targeted or semi-targeted algorithms using gene pair scoring. Differential co-expression has been used in various disease studies and identified many interesting changed interactomes of genes among different disease conditions. DiffFNs [29] , Differential co-expression [20], TSPG [39], and Topology-based cancer classification [22] were applied for the classification of tumor samples using interactome features identified using differential co-expression and shown good results over using individual gene features. The application of Ray and Zhang's coexpression network using PCC and topological overlap on Alzheimer's data helped identify gene sets whose co-expression changes in Alzheimer's patients [27] . The multi-group time-course study on ageing [19] has identified gene sets whose coexpression is modulated by ageing. Application on data of Shewanella oneidens identified a network of transcriptional regulatory relationships between chemotaxis and electron transfer pathways [32] . Many other studies have also shown the significant utility of application of differential co-expression analysis [11, 14, 33, 36] .
However, none of the existing algorithms allow direct multi-factor analysis of differential co-expression, i.e. deconvolving and quantifying the influence of different biological, environmental and clinical factors of relevance on the change in coexpression of gene sets. This is important as some phenotypes or biological outcomes are governed by multiple factors. In such a case, many single-factor differential coexpression analyses suffer from the same disadvantages of similar approach in differential expression analysis: it leads to multitude of tests, the interpretation of the identified gene sets may be cumbersome and misleading.
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Multivariate differential co-expression analysis is important in many practical settings since each sample is characterized by many factors (a.k.a. co-factors) such as environmental variables, genetic markers, genotypes, phenotypes and treatments. For example, a lung cancer sample may be characterized by EGFR expression, smoking status of the patient, KRAS mutation and age [37] . Similarly, ageing of skin may depend on age, exposure to sun, race and sex [13] . Different environmental, genetic and clinical factors may modulate co-expression of a set of genes. Deconvolving and quantifying the effects of these factors on gene set's co-expression and eliciting relevant regulatory pathways is an important task towards understanding the change in the cellular state and the underlying biology of interest.
Hence, we propose a very first methodology for such purpose called Multi-Factorial Analysis of Differential Co-eXpression or MultiDCoX, a gene set scoring based untargeted method. MultiDCoX performs greedy search for gene sets that maximize absolute coefficients of cofactors (as suggested in our earlier work [3] ) while minimizing residuals for each geneset. Though the model used in MultiDCoX is restricted to ordinal and categorical valued factors, it is not a major limitation while dealing with real valued cofactors which can be discretized into reasonably small number of levels and be treated as ordinal variables. The analysis of several simulated datasets demonstrate that the algorithm can be used to reliably identify DCX gene sets and deconvolve and quantify the influence of multiple cofactors on the co-expression of a DCX geneset in the background of large set of non-DCX gene sets. The algorithm performs well even for genesets with weak signal-to-noise ratio. The analysis of a breast cancer gene expression dataset revealed interesting biologically meaningful DCX gene sets and their relationship with the relevant cofactors.
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Furthermore, we have shown that the co-expression of CXCL13 is not only due to the Grade of the tumor as identified in [18] , but also could be influenced by ER status.
Similarly, MMP1 appears to play role in two different contexts defined by more than one co-factor. These together demonstrate the importance of multi-factor analysis.
Methods
MultiDCoX Formulation and Algorithm
MultiDCoX procedure consists of two major steps: (1) identifying DCX gene sets and obtaining respective DCX profiles; and (2) identifying covariates that influence differential co-expression of each DCX gene set. The formulation essential to carry out these two steps is as follows.
Let E im denote expression of gene g i in sample S m . The cofactor vector characterizing The linear modelling problem can be solved by standard functions (such as lm()) available in R-package. But, identifying DCX gene sets is major computational task.
The MultiDCoX algorithm identifies DCX gene sets by iteratively optimizing coefficient of a cofactor using the following procedure, see the flowchart in Figure 3 for the algorithm: (1) identifying significance threshold for cofactor coefficients; (2) choosing seed pairs of genes that demonstrate significant coefficient for the cofactor under consideration, i.e. the gene pairs may be differentially co-expressed for the cofactor; (3) expanding each chosen seed gene pair into a conservative multi-gene set by optimizing the respective coefficient; (4) augmenting the gene set to increase sensitivity or reduce false negatives while keeping the respective factor coefficient significant; and, (5) filtering out weak contributing genes from each gene set to increase specificity or reduce false positives. Each of these steps is explained in detail below. 
Identifying threshold of significance for cofactor coefficients:
where F k (I l ) is coefficient on gene set (a pair of genes in this case) I l for k th factor.
T oi is the threshold for cofactor 'i', derived from C T as follows
The division by 2 is necessary to avoid damagingly strict threshold and lay wider net at the beginning of the algorithm. m > 1 is required as some of the sampled gene pairs could belong to DCX gene sets which may overestimate the threshold and reduce sensitivity of the algorithm.
Identifying DCX seed gene pairs:
For each gene, search is performed throughout the dataset to find its partner gene whose pair can result in a linear model (Eq2) with at least one significant cofactor. A cofactor is considered to be significant if its linear model F-test p-value is < 0.01 and its coefficient is outside the range [-C T , C T ]. If no partner gene could be found, then the gene will be filtered out from the dataset to improve the computational speed at later stages of the algorithm. We have implemented this step using the procedure: (a) batch application of qr.coef() in Rpackage which computes only linear model coefficients using one QR decomposition, (b) filter out gene pairs whose linear model coefficients are in the range [-C T , C T ], (c) apply lm() on the gene pairs remaining after step 'b' to compute F-test p-values, and (d) further filter out gene pairs which do not meet requirements for the coefficient pvalue. The batch application of qr.coef() is many folds faster than lm(). We use similar strategy in the steps 3.A-3.C below to reduce computational requirements compared to the direct application of lm().
Identifying DCX gene sets:
We optimize coefficients of each significant cofactor for each gene pair in the direction, in positive or negative direction, depending on the sign of the coefficient i.e. if the coefficient is negative (positive) its minimized (maximized). To do so, for each factor, the steps 3.A-3.C are iterated until all seed pairs for which the factor is significant are exhausted from the seed pairs obtained in the step 2.
A. Expanding top gene pair to a multi-gene set:
We choose the gene pair whose constituent genes are not part of any of the multi-gene sets identified and whose linear model fit resulted in the highest coefficient for the factor of interest. It will be expanded to multi-gene set by adding genes that improve the coefficient of that factor in the direction of its coefficient for the gene pair. A sequential search is performed from first gene in the data to the last gene in the data (the order of the genes will be randomized before this sequential search). A gene is added to the set if it improved the coefficient of the factor under consideration i.e. the threshold to add a gene thereby the stringency increases as the search proceeds. The final set obtained at the end of this step is denoted by J. This step results in a most conservative DCX gene set. Factor profile FP(J) of J is defined as set of (f i ,h i ) pairs as follows:
Where f i is factor 'i' and h i denotes whether it is positively (h i =1) or negatively (h i =-1) significant or insignificant (h i =0):
3. B. Augmenting gene set J: As we tried to improve the coefficient of the factor for each addition of a gene in the expansion step (3.A), we may have missed many true positives which are not as strong constituents of J, but could be significant contributors. Therefore, we perform augmentation step to elicit some of the potential not-so strong constituents of J while preserving the factor profile of J. As the gene set identified in step (3.A) is most conservative, we set a new threshold T ni (J) or simply
T ni (J) will be as stringent as T oi and at most equal to F i (J) which is the coefficient obtained at the end of step (3.A). Moreover, we define centroid
is treated as a representative gene expression profile of J and find a gene sub set K such that each gene in K, g k , the pair K k = (g k , E C (J)) satisfies the condition 
Then the final gene set R = {g k | g k ∈ L and F(Q k ) is better than F(L)}. R is the final set output for the run.
Identifying cofactors significantly influencing DCX of each gene set: It is
important to identify the factors influencing the DCX of a gene set to interpret the geneset and elicit underlying biology, i.e. FP(R). The F-test p-value obtained for each cofactor by the linear model fit (in Eq2) in the above procedure need to be further examined owing to the dependencies among the gene sets explored. Therefore, we mark a cofactor to be influential (|hi| =1) on co-expression of R if it satisfies the following two criteria:
(a) Effect size criterion: We pool coefficients of all factors on all gene sets identified (denoted as C R ) and examine their distribution. The valleys close to zero on either side of the central peak are chosen as the significance threshold T f+ and T f-, see
assumption is that not all factors influence all gene sets and the coefficients of the factors with no or little influence on certain gene sets will be suggestive of the distribution of the coefficients under null hypothesis.
(b) Permutation p-value criterion:
We permute the factor values of a DCX gene set, i.e. permute columns of B mk matrix and fit the linear model in Eq2 for each gene set R. We repeat this procedure for a predefined number of iterations. A factor is said to be non-influential on the co-expression of the gene set under consideration if a minimum predefined fraction of permutations (0.01 in this paper) resulted in a fit in which the coefficient is better than F i (R) and its F-test p-value is better than the F-test p-value of the coefficient without permutation or 0.01 whichever is lower.
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Finally, the gene sets with at least one significant cofactor and of predefined size (i.e. at least 6 genes in the set) will be output as DCX gene sets along with their factor profiles.
Reducing computational and space requirements: Computational and space requirements can be further reduced using the following strategies: (1) Another possibility is to consider only a subset of sample pairs by randomly sampling a small fraction of (m,n)s for the linear model, it could be as small as 10% of all (m,n)s. We demonstrate the performance of the MultiDCoX even with such a minimal sampling. These three strategies put together with the optimization described in the step 2 of MultiDCoX can massively reduce the space and computational requirement by several folds and make the algorithm practically feasible.
Results
Simulation Results
To evaluate efficacy of MultiDCoX, we analysed simulated datasets of varying degrees of signal-to-noise ratio and sample size. Each simulated dataset consists of 50,000 probes as in a typical microarray and three factors of 12 stratums, sample sizes were chosen to be either 60 or 120 or 240 i.e. 5, 10 and 20 samples per stratum respectively. Two factors B1 and B2 were binary valued taking values from {-1, 1} and the other (B3) is an ordinal variable taking values from {-1, 0, 1}. Sample labels were randomly chosen for each factor and gene expression (E im ) was simulated as described below: Hence it is important to study the gene sets regulated and thereby co-expressed by these factors while accounting for the effect of the tumor status as indicated by its grade and strong association between these three factors. For example, p53-mutant tumors are typically of higher grade (grades 2 or 3) tumors with correlation ~ 63%
[40] and ER-positive tumors are typically low grade (grade 1) tumors [41] . In the presence of these correlations among the covariates, it is important to identify and quantify their effects on co-expression of gene sets. We have applied MultiDCoX on this dataset using ER status, p53 mutational status and tumor grade as cofactors. We discuss a few DCX sets here and the remaining DCX gene sets are given in the Additional File 1 (UppsalaBCResults.xlsx).
Co-expression of ER pathway and the genes associated with relevant processes is modulated in p53 mutated tumors: A DCX gene set and the linear model fit is shown
in Table 1A . The set is co-expressed only in p53 mutant tumors. The co-expression plot of p53 mutant tumors is shown in Figure 6 .
The set includes ESR1 (which encodes ERα) and its co-factor GATA3 and pioneering factor FOXA1 [23] along with ER downstream targets CA12, SPDEF and AGR2. We retrieved a total of 1349 p53 binding sites' associated genes data from Botcheva K et al. [1] , and Wei CL et al. [5] . p53 binding sites are reported to be close to the promoters of ESR1 [30] as well as GATA3. Furthermore, GATA3 appears to bind to Protein transfer associated REEP6 appears to be required to modulate ER pathway by p53.
Genes co-expressed with BRCA2 in ER-negative tumors are associated with Her2neu status:
Another gene set of interest is co-expressed in ER-negative tumors only and its details are given in Tables 2A and 2B . The co-expression plot of the gene set in ER-negative tumors is shown in Figure 7 . The gene set includes tumor suppressor gene BRCA2. We have investigated ER binding sites published by Carroll et al. [4] and Lin et al. [5] for ER binding sites close (within ±35Kb from TSS) to these genes.
The ~4800 binding sites mapped to ~1500 genes. Significantly, 10 of the 21 genes in this DCX gene set have ER binding sites mapped to them which is statistically significant at F-test p-value < 0.01. Interestingly, most of these genes have not been identified to be ER regulated in the earlier studies using differential expression methodologies, possibly owing to the complexity of regulatory mechanisms. However, many of these genes are down regulated in ER-negative tumors. Testing for association of expression of this set with Her2-neu status revealed that higher expression in ER-negative tumors is associated with Her2-neu positivity which must have led to co-expression in ER-tumors. Odds ratio of such an association is 18 which is much higher than that of ER positive tumors (OR = 4).
DCX of CXCL13 is modulated by Grade and ER status too: Analysis of Grade1 and
Grade3 tumors using GGMs [18] helped identify CXCL13 in breast cancer as hub gene. It emerged as one of the hub genes in our analysis too, contributing to multiple DCX gene sets (see Additional File 1, sheet:maxGrade). Although they are significant for Grade, they are significant for ER status too. It shows that CXCL13's differential co-expression appears to be influenced by ER status, in addition to Grade. This couldn't be identified in the previous study as it was restricted to univariate (Grade) analysis.
DCX of MMP1 is modulated by factor subspace associated with poor survival:
MMP1 is another gene we have examined whose family of genes are associated with poor survival [43] . MMP1 is co-expressed among tumors which are P53+ (mutant) and ER-negative or hi-grade tumors which are ER-postive (see Additional File 1, sheets: maxP53, maxGrade and minER). Both these categories are known to be associated with poor survival of patients. This couldn't have been revealed in a single factor analyses.
Functional analysis of DCX profiles:
To elucidate the biological function of different DCX profiles (ER+, ER-& p53+, etc.), we pooled all genes from gene sets of same DCX profile and used DAVID functional annotation tool [16] to identify GO terms, protein domains, tissues of expression and pathways enriched, the results are tabulated in Table 3 . It shows a clear distinction of GO functional categories, pathways enriched and tissues of expression between different DCX profiles. For example there is distinctive protein domains between ER-positive and ER-negative DCX profiles, whereby ER-positive's protein domain involves more in Immunoglobulin/major histocompatibility complex while ER-negative involves in epidermal growth factor (EGF) extracellular domain of membrane-bound proteins.
Also, both ER-negative and ER-positive covariates are associated with different pathway categories: ER-positive's pathway involves more in synaptic transmission, neuroactive ligand-receptor interaction while ER-negative is associated with hormone (steroid, androgen and estrogen) metabolism, drug, starch and sucrose metabolism.
The same phenomena can be observed for p53-mutant versus p53-negative associated genes.
Discussion
MultiDCoX is a space and time efficient algorithm which successfully elicits quantitative influence of cofactors on co-expression of gene sets. It required only 12 hours of computation on a typical HPC node to identify DCX gene sets for each factor for a dataset of 240 samples and ~44000 probes. The simulation results demonstrated that MultiDCoX has tolerable false discovery rates even at 5 samples/stratum and noise (σ) of 0.8. However, false negative rate (FNR) was affected by both sample size and noise level. As expected, FNR is very low for large sample size (20 samples per stratum) and low noise level (σ = 0.2). Interestingly, both FDR and FNR did not greatly depended on the type of the gene set to be discovered, or whether it is influenced by single factor or multi-factors. The discovery of a gene set whose DCX is driven by two cofactors is less affected by noise and sample size than the gene sets influenced by a single cofactor. On the other hand, the set influenced by 2-cofactors has higher likelihood of arriving at the wrong profile compared to that of a 1-cofactor driven DCX. Occurrence of false DCX sets increased with increasing noise level, it is pronounced more for small sample size case. This is a major issue to be addressed in the future improvements over the current version of MultiDCoX. Moreover, the performance of the algorithm needs to be studied for varying parameters' settings and further reductions in computational time. It is possible to reduce the computational time by 2 fold by filtering out 50% of probes of low variance in expression. Though we have not used this strategy as we needed to study its impact on the discovery and profiling of DCX gene sets, the current implementation could complete the analysis within half a day of computing for each factor. The massive parallel processing allows us to complete all analyses within a day.
By MultiDCoX formulation, we identify DCX gene sets exhibiting B-type coexpression only [3] . The other two types of differential co-expression may be identified using multivariate differential expression analysis followed by clustering.
MultiDCoX algorithm can be applied to different clinical data to quantify the influence of multiple cofactors on the co-expression and its associated phenotypes.
Multiple aspects of the formulation and the algorithm need to be studied in our future improvements: Robustness of A mn (I) to outliers is an important aspects of the performance of the algorithm and impact of the thresholds used in the algorithm also to be studied. However, without tuning, the choice of parameters appears to be effective enough for both simulated and real data sets.
The application of MultiDCoX on a breast cancer data has revealed interesting sets of DCX genes: the set of ESR1, its cofactors along with downstream genes of ESR1 and genes associated with relevant ESR1 dependent transcriptional regulation; the set of genes containing ER binding site in their cis region. Furthermore, we have shown that the co-expression of gene sets that contain CXCL13 and the gene sets that contain MMP1 is affected by ER status too in addition to tumor grade which couldn't have been elicited in a typical univariate DCX analysis. 
Declarations
Legend -Figures
Figure 1 -Differential Co-Expression.
Geneset is co-expressed in normal samples but not in disease samples. 
Figure 5 -Simulation results
The simulations were carried out for 5 samples/stratum, 10 samples/stratum and 20 samples/stratum. Set 1 represents gene set simulated to be co-expressed only in samples B1 m = -1, while Set 2 represents gene set simulated to be co-expressed for B1 m =1 and B2 m =1. b) The geneset 2 showed no co-expression in ER-positive tumor samples; gray line indicates mean expression value. Table 1 A) The table shows the MultiDCoX model fit over three factors (ER, p53 and Grade) . A gene set identified is differentially co-expressed in p53+ with F-test p-value = 2.75 x 10 -231 and coefficients value = 1.137. Only p53 covariate is significant and its coefficient is positive which means the co-expression of the set occurs only in p53 mutant tumors only.
Legend -Tables
B) ER dependent differential expression, ER binding sites and p53 binding sites for the geneset in Table 1A . Table 2 A) The table shows the MultiDCoX model fit over three factors (ER, p53 and Grade). A gene set identified is differentially co-expressed in ER-negative covariate with F-test p-value = 1.34 x 10 -252 and coefficients value = -1.117. Only ER covariate is significant and its coefficient is negative which means the co-expression of the set occurs in ER-negative tumors only.
B) ER dependent differential expression, ER binding sites and p53 binding sites for the gene set in Table 2A . Table 3 
-Functional analysis of co-expression in different covariates
GO (Gene ontology) summary shows gene sets, GO terms enriched and the influence of different cofactors. For each covariate, the sets with positive coefficient are pooled and analyzed for GO and pathway enrichment, it is repeated for the sets with negative coefficient as well. Tables   Table 1A. The table shows the MultiDCoX model fit over three factors (ER, p53 and   Grade) . A gene set identified is differentially co-expressed in p53+ with F-test p-value = 2.75 x 10 -231 and coefficients value = 1.137. Only p53 covariate is significant and its coefficient is positive which means the co-expression of the set occurs only in p53 mutant tumors only. 
